1. Home
  2. SBR vs IOVA Comparison

SBR vs IOVA Comparison

Compare SBR & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sabine Royalty Trust

SBR

Sabine Royalty Trust

HOLD

Current Price

$69.55

Market Cap

1.0B

Sector

Energy

ML Signal

HOLD

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$2.54

Market Cap

881.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBR
IOVA
Founded
1982
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
881.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SBR
IOVA
Price
$69.55
$2.54
Analyst Decision
Buy
Analyst Count
0
12
Target Price
N/A
$10.45
AVG Volume (30 Days)
32.8K
12.5M
Earning Date
02-27-2026
02-26-2026
Dividend Yield
7.24%
N/A
EPS Growth
N/A
N/A
EPS
5.44
N/A
Revenue
$83,430,550.00
$250,425,000.00
Revenue This Year
N/A
$60.71
Revenue Next Year
N/A
$59.35
P/E Ratio
$12.79
N/A
Revenue Growth
N/A
175.62
52 Week Low
$58.25
$1.64
52 Week High
$84.39
$6.16

Technical Indicators

Market Signals
Indicator
SBR
IOVA
Relative Strength Index (RSI) 50.32 47.81
Support Level $69.50 $2.25
Resistance Level $72.50 $2.77
Average True Range (ATR) 1.40 0.22
MACD 0.18 -0.03
Stochastic Oscillator 44.27 31.01

Price Performance

Historical Comparison
SBR
IOVA

About SBR Sabine Royalty Trust

Sabine Royalty Trust is an express trust which is formed to receive Sabine Corporation's royalty and mineral interests, including landowner's royalties, overriding royalty interests, minerals production payments and any other similar, non-participatory interests, in certain Royalty Properties. The trusts producing and proved undeveloped oil and gas royalty properties are located in Florida, Louisiana, Mississippi, New Mexico, Oklahoma, and Texas.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Share on Social Networks: